



Samrat Pharmachem Limited

Manufacturers, Importers & Exporters of Pharmaceutical Chemicals

Regd Office : Plot No. A2/3445, GIDC Phase 4, Ankleshwar - 393 002, Gujarat

Corp Office : 701/702, Business Square, M. A. Road, Andheri (West), Mumbai - 400 058.

CIN : L24230GJ1992PLC017820

Statement of Standalone Unaudited Results for the Quarter ended 31 December, 2015

(Rs. In Lakhs)

Particulars	Quarter Ended			Nine Months Ended		Previous Year Ended
	31-Dec-15	30-Sep-15	31-Dec-14	31-Dec-15	31-Dec-14	31-Mar-15
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 (a). Net Income from Sales / Services	1,654.23	1,277.40	899.25	4,188.16	3,821.75	4,739.44
(b). Other Operating Income	2.55	1.26	0.89	4.67	15.92	17.36
Total Income	1,656.78	1,278.66	900.14	4,192.83	3,837.67	4,756.80
2. Expenditure						
a) Cost of Materials Consumed	1,116.45	1,116.73	743.48	3,443.67	3,084.86	3,849.60
b) Purchase of Traded Goods	320.58	87.27	0.00	407.85	216.73	216.73
c) (Increase)/Decrease in Stock in Trade & WIP	73.17	(57.54)	42.60	(51.65)	160.76	204.58
d) Employee benefits expense	24.75	21.25	23.50	66.25	62.37	91.20
e) Depreciation	11.18	11.09	8.94	33.11	26.48	43.76
f) Other Expenditure						
(i) Manufacturing Expenses	42.27	46.69	40.56	137.06	103.52	157.28
(ii) Administration Expenses	12.95	19.81	15.60	44.40	43.43	59.65
(iii) Selling & Distribution Expenses	30.45	20.98	12.75	59.76	37.42	44.96
g) Total	1,631.80	1,266.28	887.43	4,140.45	3,735.57	4,667.76
3. Profit from Operations before Other Income, Interest and Exceptional Items	24.98	12.38	12.71	52.38	102.10	89.04
4. Other Income	4.19	4.38	3.93	11.41	12.51	17.41
5. Profit before Interest and Exceptional items	29.17	16.76	16.64	63.79	114.61	106.45
6. Finance Costs	22.65	11.91	10.26	40.44	47.29	58.55
7. Profit after Finance costs but before Exceptional items	6.52	4.85	6.38	23.35	67.32	47.90
8. Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00
9. Profit / (Loss) from ordinary activities before tax	6.52	4.85	6.38	23.35	67.32	47.90
10. Tax expense (incl deferred tax)	(5.50)	(0.51)	(4.01)	(10.83)	(26.80)	(16.31)
11. Net Profit / (Loss) from ordinary activities after tax	1.02	4.34	2.37	12.52	40.52	31.59
12. Extraordinary Items (Net of tax expense Rs. _____)	0.00	0.00	0.00	0.00	0.00	0.00
13. Net Profit / (Loss) for the period	1.02	4.34	2.37	12.52	40.52	31.59
14. Share of Profit / (loss) of associates	0.00	0.00	0.00	0.00	0.00	0.00
15. Minority Interest	0.00	0.00	0.00	0.00	0.00	0.00
16. Net Profit / (Loss) after tax, share of profit/loss of associates and minority interest	1.02	4.34	2.37	12.52	40.52	31.59
17. Paid-up Equity Share Capital (Face Value Rs.10)	308.97	308.97	308.97	308.97	308.97	308.97
18. Reserves excluding revaluation reserves	1,048.91	1,047.90	1,044.22	1,048.91	1,044.22	1,036.51
19. Earnings per share						
a) Basic and diluted EPS before extraordinary items for the period, year-to-date, previous year	0.03	0.14	0.08	0.41	1.31	1.02
b) Basic and diluted EPS after extraordinary items for the period, year-to-date, previous year	0.03	0.14	0.08	0.41	1.31	1.02
20. Public shareholding						
-- Number of shares	1,631,553	1,631,553	1,638,076	1,631,553	1,638,076	1,633,715
-- Percentage of shareholding	52.81	52.81	53.02	52.81	53.02	52.88
21. Promoters and promoter group shareholding						
a) Pledged/ Encumbered						
-- Number of shares	0.00	0.00	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00	0.00	0.00	0.00	0.00	0.00
-- Percentage of shares (as a % of the total share capital of the company)	0.00	0.00	0.00	0.00	0.00	0.00
b) Non-encumbered						
-- Number of shares	1,458,147	1,458,147	1,451,624	1,458,147	1,451,624	1,455,985
-- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00	100.00	100.00
-- Percentage of shares (as a % of the total share capital of the company)	47.19	47.19	46.98	47.19	46.98	47.12

Notes:

- The above results were reviewed by the Audit Committee of the Board of Directors.
- The Statutory Auditors have carried out a limited review of the results for the quarter ended 31 December, 2015.
- The above results have been taken on record by the Board of Directors at its Meeting held on Saturday, 13 February 2016 at the Corporate Office of the Company.
- Previous period / year's figures have been regrouped and rearranged wherever necessary.
- Information on investor complaints pursuant to clause 41 of the listing agreement for the quarter ended 31 December, 2015

Opening Balance as on	1/Oct/2015	0
Received during the quarter		0
Disposed of during the quarter		0
Closing Balance as on	31/Dec/2015	0

By order of the Board of Directors
For Samrat Pharmachem Limited

Place : Mumbai
Date : 13 February 2016

Rajesh Mehta
Director